Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Trading assets

Trading assets at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
——

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's trading assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's trading assets?
BioCryst Pharmaceuticals (BCRX) reported trading assets of $66.81M in Q1 2026.
How has BioCryst Pharmaceuticals's trading assets changed year-over-year?
BioCryst Pharmaceuticals's trading assets decreased by 64.8% year-over-year, from $189.9M to $66.81M.
What is the long-term trend for BioCryst Pharmaceuticals's trading assets?
Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's trading assets has grown at a 15.7% compound annual growth rate (CAGR), from $119.54M to $185.01M.
What does trading assets mean?
Securities and other financial instruments held for short-term trading purposes, measured at fair value with changes flowing through the income statement.